Zynex, Inc. (USD) Zynex, Inc., operating through its subsidiaries, specializes in the development, production, and sale of medical devices. These devices primarily utilize electrical stimulation to alleviate both chronic and acute pain, and to stimulate and exercise muscles for rehabilitation. The company's core product offerings include NexWave, a versatile, dual-channel device combining interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation (NMES), which is actively marketed to physicians and therapists by its field sales force. Other significant products are NeuroMove, an electrical stimulator activated by electromyography; InWave, specifically designed for treating female urinary incontinence; and E-Wave, another type of NMES device. Zynex also provides private-label accessories, such as electrodes for conducting electrical currents to the body and batteries for powering electrotherapy products. Beyond its own manufactured goods, the company acts as a distributor for several third-party medical items. These include Comfortrac/Saunders for cervical traction, JetStream for therapeutic hot/cold applications, LSO Back Braces for lumbar support, and various knee braces. Expanding its technological portfolio, Zynex offers advanced monitoring solutions. This includes the Zynex Fluid Monitoring System (CM-1500), a non-invasive device that tracks relative fluid volume changes in surgical and recovery settings to identify fluid loss during operations or internal bleeding afterward. A wireless version, the CM-1600, provides similar non-invasive fluid volume monitoring for adult patients. Additionally, the company supplies the NiCO CO-Oximeter and the HemeOx tHb Oximeter, both non-invasive, laser-based devices for co-oximetry and total hemoglobin pulse oximetry, respectively. Zynex's diverse product range is utilized across various medical applications, including pain management, rehabilitation for stroke and spinal cord injuries, hemodynamic monitoring, and pulse oximetry. The company distributes its products primarily through its direct sales force, mainly within the United States. Established in 1996, Zynex, Inc. is based in Englewood, Colorado.

Zynex, Inc. (USD) Passive

9655 Maroon Circle, Englewood, CO, US, 80112

Stock Price USD

Price Change

Last Dividend USD

ZYXI's stock peer is ECOR (electroCore, Inc.)

ZYXI's stock peer is EVAX (Evaxion Biotech A/S)

ZYXI's stock peer is GBIO (Generation Bio Co.)

ZYXI's stock peer is HYPD (Hyperion DeFi, Inc.)

ZYXI's stock peer is JSPR (Jasper Therapeutics, Inc.)

ZYXI's stock peer is MAIA (MAIA Biotechnology, Inc.)

ZYXI's stock peer is MODD (Modular Medical, Inc.)

ZYXI's stock peer is MURA (Mural Oncology plc)

ZYXI's stock peer is WGRX (Wellgistics Health, Inc.)

Healthcare Medical - Distribution

Zynex, Inc., operating through its subsidiaries, specializes in the development, production, and sale of medical devices. These devices primarily utilize electrical stimulation to alleviate both chronic and acute pain, and to stimulate and exercise muscles for rehabilitation. The company's core product offerings include NexWave, a versatile, dual-channel device combining interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation (NMES), which is actively marketed to physicians and therapists by its field sales force. Other significant products are NeuroMove, an electrical stimulator activated by electromyography; InWave, specifically designed for treating female urinary incontinence; and E-Wave, another type of NMES device. Zynex also provides private-label accessories, such as electrodes for conducting electrical currents to the body and batteries for powering electrotherapy products. Beyond its own manufactured goods, the company acts as a distributor for several third-party medical items. These include Comfortrac/Saunders for cervical traction, JetStream for therapeutic hot/cold applications, LSO Back Braces for lumbar support, and various knee braces. Expanding its technological portfolio, Zynex offers advanced monitoring solutions. This includes the Zynex Fluid Monitoring System (CM-1500), a non-invasive device that tracks relative fluid volume changes in surgical and recovery settings to identify fluid loss during operations or internal bleeding afterward. A wireless version, the CM-1600, provides similar non-invasive fluid volume monitoring for adult patients. Additionally, the company supplies the NiCO CO-Oximeter and the HemeOx tHb Oximeter, both non-invasive, laser-based devices for co-oximetry and total hemoglobin pulse oximetry, respectively. Zynex's diverse product range is utilized across various medical applications, including pain management, rehabilitation for stroke and spinal cord injuries, hemodynamic monitoring, and pulse oximetry. The company distributes its products primarily through its direct sales force, mainly within the United States. Established in 1996, Zynex, Inc. is based in Englewood, Colorado.

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
2022-01-06	2022-01-21	0.10	0.98 %	Special
2019-01-02	2019-01-18	0.07	2.41 %	Special
		0.15	43.44 %	Special

Recent News

ZYXIQ CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Zynex between February 25, 2021 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - April 21, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zynex, Inc. ("Zynex" or the "Company") (OTC Pink: ZYXIQ) and reminds investors of the April 21, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

2026-04-21 15:24:00

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 21, 2026 in Zynex, Inc. Lawsuit – ZYXIQ

NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zynex, Inc. ("Zynex, Inc." or the "Company") (OTC PINK: ZYXIQ) of a class action securities lawsuit.

2026-04-20 16:00:00

Bronstein, Gewirtz & Grossman LLC Urges Zynex, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Zynex, Inc. (ZYXIQ) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/21/2026

2026-04-20 12:00:00

Bronstein, Gewirtz & Grossman LLC Urges Zynex, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New York, New York--(Newsfile Corp. - April 20, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Zynex, Inc. (OTC Pink: ZYXIQ) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zynex securities between February 25, 2021 and December 15, 2025, both dates inclusive (the "Class Period").

2026-04-20 12:00:00

ZYXIQ SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Zynex between February 25, 2021 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - April 19, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zynex, Inc. ("Zynex" or the "Company") (OTC Pink: ZYXIQ) and reminds investors of the April 21, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

2026-04-19 08:28:00

Bronstein, Gewirtz & Grossman LLC Urges Zynex, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New York, New York--(Newsfile Corp. - April 17, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Zynex, Inc. (OTC Pink: ZYXIQ) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zynex securities between February 25, 2021 and December 15, 2025, both dates inclusive (the "Class Period").

2026-04-17 14:20:00

Bronstein, Gewirtz & Grossman LLC Urges Zynex, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Zynex, Inc. (ZYXIQ) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/21/2026

2026-04-17 12:00:00

ZYXIQ Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Zynex, Inc. Securities Lawsuit — The Gross Law Firm

NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zynex, Inc. (OTC PINK: ZYXIQ).

2026-04-17 09:00:00

ZYXIQ UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Zynex between February 25, 2021 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, April 17, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zynex, Inc. ("Zynex" or the "Company") (OTCPK: ZYXIQ) and reminds investors of the April 21, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

2026-04-17 08:50:00

Bronstein, Gewirtz & Grossman LLC Urges Zynex, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New York, New York--(Newsfile Corp. - April 16, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Zynex, Inc. (OTC Pink: ZYXIQ) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zynex securities between February 25, 2021 and December 15, 2025, both dates inclusive (the "Class Period").

2026-04-16 14:15:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions